Epidemiology, Real-World Treatment Patterns, and Patient Outcomes of Primary Advanced or Recurrent Endometrial Cancer in Germany Between 2015 and 2021

Overview

Journal Oncol Res Treat

Specialty Oncology

Date 2024 Nov 27

PMID 39602910

Authors

Antje Mevius

Johanna Lutter

Florian M Karl

Liam Tuffy

Fabienne Schochter

Andreas Fuchs

Thomas Wilke

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of this study was to describe the epidemiology of primary advanced or recurrent endometrial cancer and the outcomes from real-world treatment patterns of patients affected in Germany between 2015 and 2021.

Methods: In this retrospective cohort study covering the period from 1 January 2015 to 31 December 2021, data from patients with primary advanced or recurrent endometrial cancer who initiated systemic treatment for their disease were extracted from an anonymized claims dataset from a regional health insurance fund in the German states of Saxony and Thuringia. Epidemiologic outcomes were cumulative incidence of endometrial cancer and point prevalence. Overall survival after the index date was assessed, with all-cause death used as an event. Endometrial cancer-related real-world treatment patterns were described for the post-index period.

Results: The incidence of primary advanced or recurrent endometrial cancer in 2021 was 4.77 cases/100,000 persons, with no substantial change over time (4.63 in 2018; 4.93 in 2019; 4.45 in 2020). The point prevalence on 1 January 2022 was 0.023%, with a slight increase in prevalence observed from 1 January 2019 onwards. Among 466 patients with confirmed endometrial cancer, the mean (standard deviation) age was 68.0 (11.6) years; the tumor material from 86 patients (18.5%) underwent immunohistochemistry or polymerase chain reaction testing. Median overall survival was estimated to be 47.5 months (95% CI: 35.1-70.4) and the 5-year survival probability was 46.2%. The most frequent first-line systemic therapies were carboplatin (45.7%) and paclitaxel (43.1%). Second-line therapy was received by 153 patients (32.8%).

Conclusion: The analysis of the German claims data produced contemporary epidemiologic estimates for advanced or recurrent endometrial cancer. Treatments were aligned with guideline recommendations during the study period, with tumor testing yet to enter mainstream practice.

References

Kebede N, Shah R, Shah A, Corman S, Nwankwo C . Treatment patterns and economic burden among cervical and endometrial cancer patients newly initiating systemic therapy. Future Oncol. 2022; 18(8):953-964. DOI: 10.2217/fon-2021-0772. View

Herbst F, Dickman P, Moberg L, Hogberg T, Borgfeldt C . Increased incidence and improved survival in endometrial cancer in Sweden 1960-2014: a population-based registry survey. BMC Cancer. 2023; 23(1):276. PMC: 10045609. DOI: 10.1186/s12885-023-10746-0. View

Westin S, Moore K, Chon H, Lee J, Pepin J, Sundborg M . Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol. 2023; 42(3):283-299. PMC: 10824389. DOI: 10.1200/JCO.23.02132. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Oaknin A, Bosse T, Creutzberg C, Giornelli G, Harter P, Joly F . Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 33(9):860-877. DOI: 10.1016/j.annonc.2022.05.009. View

Paleari L, Pesce S, Rutigliani M, Greppi M, Obino V, Gorlero F . New Insights into Endometrial Cancer. Cancers (Basel). 2021; 13(7). PMC: 8037936. DOI: 10.3390/cancers13071496. View

Bestvina C, Fleming G . Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings. Oncologist. 2016; 21(10):1250-1259. PMC: 5061541. DOI: 10.1634/theoncologist.2016-0062. View

Mevius A, Karl F, Wacker M, Welte R, Krenzer S, Link T . Real-world treatment of German patients with recurrent and advanced endometrial cancer with a post-platinum treatment: a retrospective claims data analysis. J Cancer Res Clin Oncol. 2022; 149(5):1929-1939. PMC: 10097742. DOI: 10.1007/s00432-022-04183-y. View

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J . ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015; 27(1):16-41. DOI: 10.1093/annonc/mdv484. View

10.

Knisely A, Huang Y, Li Y, Prabhu V, Wright J . Adjuvant and first line chemotherapy use for endometrial cancer. Gynecol Oncol Rep. 2022; 41:101002. PMC: 9126968. DOI: 10.1016/j.gore.2022.101002. View

11.

Monk B, Smith G, Lima J, Long G, Alam N, Nakamura H . Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records. Gynecol Oncol. 2021; 164(2):325-332. DOI: 10.1016/j.ygyno.2021.12.008. View

12.

Miller D, Filiaci V, Mannel R, Cohn D, Matsumoto T, Tewari K . Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020; 38(33):3841-3850. PMC: 7676887. DOI: 10.1200/JCO.20.01076. View

13.

Laine A, Gonzalez-Lopez A, Hasan U, Ohkuma R, Ray-Coquard I . Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors. Cancers (Basel). 2023; 15(7). PMC: 10093320. DOI: 10.3390/cancers15072042. View

14.

Lortet-Tieulent J, Ferlay J, Bray F, Jemal A . International Patterns and Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2017; 110(4):354-361. DOI: 10.1093/jnci/djx214. View

15.

Chae J, Song C, Kim H, Lee K, Seo B, Kim D . Prediction of mortality in patients undergoing maintenance hemodialysis by Charlson Comorbidity Index using ICD-10 database. Nephron Clin Pract. 2010; 117(4):c379-84. DOI: 10.1159/000321525. View

16.

Emons G, Steiner E, Vordermark D, Uleer C, Paradies K, Tempfer C . Endometrial Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry Number 032/034-OL, September 2022). Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer, Geriatric.... Geburtshilfe Frauenheilkd. 2023; 83(8):919-962. PMC: 10427205. DOI: 10.1055/a-2066-2051. View

17.

Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza M, Marnitz S . ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021; 31(1):12-39. DOI: 10.1136/ijgc-2020-002230. View

18.

Martins D, OSullivan D, Boyne D, Cheung W, Allonby O, Habash M . Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study. Curr Oncol. 2023; 30(2):2277-2289. PMC: 9955469. DOI: 10.3390/curroncol30020176. View

19.

Eskander R, Sill M, Beffa L, Moore R, Hope J, Musa F . Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med. 2023; 388(23):2159-2170. PMC: 10351614. DOI: 10.1056/NEJMoa2302312. View

20.

Mirza M, Chase D, Slomovitz B, Christensen R, Novak Z, Black D . Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023; 388(23):2145-2158. DOI: 10.1056/NEJMoa2216334. View